Document:

<PAGE>
                                                                    EXHIBIT 10.1

                           CYTOKINETICS, INCORPORATED

                            INDEMNIFICATION AGREEMENT

     This Indemnification Agreement ("AGREEMENT") is made as of this ___ day of
___________, ______, by and between Cytokinetics, Incorporated, a Delaware
corporation (the "COMPANY"), and _____________________ ("INDEMNITEE").

     WHEREAS, the Company and Indemnitee recognize the significant cost of
directors' and officers' liability insurance and the general reductions in the
coverage of such insurance;

     WHEREAS, the Company and Indemnitee further recognize the substantial
increase in corporate litigation in general, subjecting officers and directors
to expensive litigation risks at the same time as the coverage of liability
insurance has been severely limited; and

     WHEREAS, the Company desires to attract and retain the services of highly
qualified individuals, such as Indemnitee, to serve as officers and directors of
the Company and to indemnify its officers and directors so as to provide them
with the maximum protection permitted by law.

     NOW, THEREFORE, in consideration for Indemnitee's services as an officer or
director of the Company, the Company and Indemnitee hereby agree as follows:

     1. INDEMNIFICATION.

          (a) THIRD PARTY PROCEEDINGS. The Company shall indemnify Indemnitee if
Indemnitee is or was a party or is threatened to be made a party to any
threatened, pending or completed action, suit, proceeding or any alternative
dispute resolution mechanism, whether civil, criminal, administrative or
investigative (other than an action by or in the right of the Company) by reason
of the fact that Indemnitee is or was a director, officer, employee or agent of
the Company, or any subsidiary of the Company, by reason of any action or
inaction on the part of Indemnitee while serving in Indemnitee's capacity as a
director, officer, employee or agent of the Company or by reason of the fact
that Indemnitee is or was serving at the request of the Company as a director,
officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise, against expenses (including attorneys' fees),
judgments, fines and amounts paid in settlement (if such settlement is approved
in advance by the Company, which approval shall not be unreasonably withheld)
actually and reasonably incurred by Indemnitee in connection with such action,
suit or proceeding if Indemnitee acted in good faith and in a manner Indemnitee
reasonably believed to be in or not opposed to the best interests of the
Company, and, with respect to any criminal action or proceeding, had no
reasonable cause to believe Indemnitee's conduct was unlawful. The termination
of any action, suit or proceeding by judgment, order, settlement, conviction, or
upon a plea of NOLO CONTENDERE or its equivalent, shall not, of itself, create a
presumption that Indemnitee did not act in good faith and in a manner which
Indemnitee reasonably believed to be in or not opposed to the best

<PAGE>

interests of the Company, and, with respect to any criminal action or
proceeding, had reasonable cause to believe that Indemnitee's conduct was
unlawful.

          (b) PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY. The Company shall
indemnify Indemnitee if Indemnitee was or is a party or is threatened to be made
a party to any threatened, pending or completed action, suit or proceeding by or
in the right of the Company or any subsidiary of the Company to procure a
judgment in its favor by reason of the fact that Indemnitee is or was a
director, officer, employee or agent of the Company, or any subsidiary of the
Company, by reason of any action or inaction on the part of Indemnitee while
serving in Indemnitee's capacity as a director, officer, employee or agent of
the Company or by reason of the fact that Indemnitee is or was serving at the
request of the Company as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys' fees) and, to the fullest extent permitted by
law, amounts paid in settlement in each case to the extent actually and
reasonably incurred by Indemnitee in connection with the defense or settlement
of such action, suit or proceeding if Indemnitee acted in good faith and in a
manner Indemnitee reasonably believed to be in or not opposed to the best
interests of the Company, except that no indemnification shall be made in
respect of any claim, issue or matter as to which Indemnitee shall have been
finally adjudicated by court order or judgment (for which no further right of
appeal exists) to be liable to the Company in the performance of Indemnitee's
duty to the Company unless and only to the extent that the Court of Chancery of
the State of Delaware or the court in which such action or suit was brought
shall determine upon application that, despite the adjudication of liability but
in view of all the circumstances of the case, Indemnitee is fairly and
reasonably entitled to indemnity for such expenses which the Court of Chancery
of the State of Delaware or such other court shall deem proper.

          (c) MANDATORY PAYMENT OF EXPENSES. To the extent that Indemnitee has
been successful on the merits or otherwise in defense of any action, suit or
proceeding referred to in Subsections (a) and (b) of this Section 1, or in
defense of any claim, issue or matter therein, Indemnitee shall be indemnified
against expenses (including attorneys' fees) actually and reasonably incurred by
Indemnitee in connection therewith. Without limiting the foregoing, if any
action, suit or proceeding is disposed of, on the merits or otherwise (including
a disposition without prejudice), without (i) the disposition being adverse to
the Indemnitee, (ii) an adjudication that the Indemnitee was liable to the
Company, (iii) a plea of guilty or nolo contendere by the Indemnitee, (iv) an
adjudication that the Indemnitee did not act in good faith and in a manner he
reasonably believed to be in or not opposed to the best interests of the
Company, and (v) with respect to any criminal proceeding, an adjudication that
the Indemnitee had reasonable cause to believe his conduct was unlawful, the
Indemnitee shall be considered for the purpose hereof to have been wholly
successful with respect thereto.

     2. EXPENSES; INDEMNIFICATION PROCEDURE.

          (a) ADVANCEMENT OF EXPENSES. The Company shall advance all expenses
incurred by Indemnitee in connection with the investigation, defense, settlement
or appeal of any civil or criminal action, suit or proceeding referenced in
Section 1(a) or (b) hereof (but not amounts actually paid in settlement of any
such action, suit or proceeding). Indemnitee hereby undertakes to repay such
amounts advanced only if, and to the extent that, it shall ultimately be
determined that

                                      -2-
<PAGE>

Indemnitee is not entitled to be indemnified by the Company as authorized
hereby. The advances to be made hereunder shall be paid by the Company to
Indemnitee within thirty (30) days following delivery of a written request
therefor by Indemnitee to the Company.

          (b) NOTICE/COOPERATION BY INDEMNITEE. Indemnitee shall, as a condition
precedent to his right to be indemnified under this Agreement, give the Company
notice in writing as soon as practicable of any claim made against Indemnitee
for which indemnification will or could be sought under this Agreement. Notice
to the Company shall be directed to the President of the Company at the address
shown on the signature page of this Agreement (or such other address as the
Company shall designate in writing to Indemnitee). Notice shall be deemed
received three business days after the date postmarked if sent by domestic
certified or registered mail, properly addressed, five business days if sent by
airmail to a country outside of North America; otherwise notice shall be deemed
received when such notice shall actually be received by the Company. In
addition, Indemnitee shall give the Company such information and cooperation as
it may reasonably require and as shall be within Indemnitee's power.

          (c) PROCEDURE. Any indemnification and advances provided for in
Section 1 and this Section 2 shall be made promptly, and in any event no later
than thirty (30) days after receipt of the written request of Indemnitee. If a
claim under this Agreement, under any statute, or under any provision of the
Company's Certificate of Incorporation or Bylaws providing for indemnification,
is not paid in full by the Company within thirty (30) days after a written
request for payment thereof has first been received by the Company, Indemnitee
may, but need not, at any time thereafter bring an action against the Company to
recover the unpaid amount of the claim and, subject to Section 12 of this
Agreement, Indemnitee shall also be entitled to be paid for the expenses
(including attorneys' fees) of bringing such action. It shall be a defense to
any such action (other than an action brought to enforce a claim for expenses
incurred in connection with any action, suit or proceeding in advance of its
final disposition) that Indemnitee has not met the standards of conduct which
make it permissible under applicable law for the Company to indemnify Indemnitee
for the amount claimed but the burden of proving such defense shall be on the
Company and Indemnitee shall be entitled to receive interim payments of expenses
pursuant to Subsection 2(a) unless and until such defense may be finally
adjudicated by court order or judgment from which no further right of appeal
exists. It is the parties' intention that if the Company contests Indemnitee's
right to indemnification, the question of Indemnitee's right to indemnification
shall be for the court to decide, and neither the failure of the Company
(including its Board of Directors, any committee or subgroup of the Board of
Directors, independent legal counsel, or its stockholders) to have made a
determination that indemnification of Indemnitee is proper in the circumstances
because Indemnitee has met the applicable standard of conduct required by
applicable law, nor an actual determination by the Company (including it Board
of Directors, any committee or subgroup of the Board of Directors, independent
legal counsel, or its stockholders) that Indemnitee has not met such applicable
standard of conduct, shall create a presumption that Indemnitee has or has not
met the applicable standard of conduct.

          (d) NOTICE TO INSURERS. If, at the time of the receipt of a notice of
a claim pursuant to Section 2(b) hereof, the Company has director and officer
liability insurance in effect, the Company shall give prompt notice of the
commencement of such proceeding to the insurers in accordance with

                                      -3-
<PAGE>

the procedures set forth in the respective policies. The Company shall
thereafter take all necessary or desirable action to cause such insurers to pay,
on behalf of the Indemnitee, all amounts payable as a result of such proceeding
in accordance with the terms of such policies.

          (e) SELECTION OF COUNSEL. In the event the Company shall be obligated
under Section 2(a) hereof to pay the expenses of any proceeding against
Indemnitee, the Company, if appropriate, shall be entitled to assume the defense
of such proceeding, with counsel approved by Indemnitee, upon the delivery to
Indemnitee of written notice of its election to do so. Notwithstanding the
foregoing, the Company shall not be permitted to settle any action or claim on
behalf of Indemnitee in any manner which would impose any unindemnified
liability or penalty on the Indemnitee or require any acknowledgement of
wrongdoing on the part of the Indemnitee without Indemnitee's written consent,
which consent shall not be unreasonably withheld. The Company agrees that it
will not, without the prior written consent of the Indemnitee, settle,
compromise or consent to the entry of any judgment in any pending or threatened
claim relating to the matters contemplated hereby (if the Indemnitee is a party
thereto or has been threatened to be made or would reasonably be expected to be
made a party thereto) unless such settlement, compromise or consent includes an
unconditional release of the Indemnitee from all liability arising or that may
arise out of such claim. The Indemnitee shall not be liable for any settlement
of any claim effected against the Indemnitee without Indemnitee's written
consent. After delivery of such notice, approval of such counsel by Indemnitee
and the retention of such counsel by the Company, the Company will not be liable
to Indemnitee under this Agreement for any fees of counsel subsequently incurred
by Indemnitee with respect to the same proceeding, provided that (i) Indemnitee
shall have the right to employ his counsel in any such proceeding at
Indemnitee's expense; and (ii) if (A) the employment of counsel by Indemnitee
has been previously authorized by the Company, (B) Indemnitee shall have
reasonably concluded that there may be a conflict of interest between the
Company and Indemnitee in the conduct of any such defense, or (C) the Company
shall not, in fact, have employed counsel to assume the defense of such
proceeding, then the fees and expenses of Indemnitee's counsel shall be at the
expense of the Company. The Company shall not be entitled, without the consent
of the Indemnitee, to assume the defense of any claim brought by or in the right
of the Company or as to which counsel for the Indemnitee shall have reasonably
made the conclusion provided for in clause (ii)(B) above.

     3. ADDITIONAL INDEMNIFICATION RIGHTS; NONEXCLUSIVITY.

          (a) SCOPE. Notwithstanding any other provision of this Agreement, the
Company hereby agrees to indemnify the Indemnitee to the fullest extent
permitted by law, notwithstanding that such indemnification is not specifically
authorized by the other provisions of this Agreement, the Company's Certificate
of Incorporation, the Company's Bylaws or by statute. In the event of any
change, after the date of this Agreement, in any applicable law, statute, or
rule which expands the right of a Delaware corporation to indemnify a member of
its board of directors or an officer, such changes shall be, IPSO FACTO, within
the purview of Indemnitee's rights and Company's obligations, under this
Agreement. In the event of any change in any applicable law, statute or rule
which narrows the right of a Delaware corporation to indemnify a member of its
board of directors or an officer, such changes, to the extent not otherwise
required by such law, statute or rule to be applied

                                      -4-
<PAGE>

to this Agreement shall have no effect on this Agreement or the parties' rights
and obligations hereunder.

          (b) NONEXCLUSIVITY. The indemnification provided by this Agreement
shall not be deemed exclusive of any rights to which Indemnitee may be entitled
under the Company's Certificate of Incorporation, its Bylaws, any agreement, any
vote of stockholders or disinterested Directors, the General Corporation Law of
the State of Delaware, or otherwise, both as to action in Indemnitee's official
capacity and as to action in another capacity while holding such office. The
indemnification provided under this Agreement shall continue as to Indemnitee
for any action taken or not taken while serving in an indemnified capacity even
though he may have ceased to serve in such capacity at the time of any action,
suit or other covered proceeding.

     4. PARTIAL INDEMNIFICATION. If Indemnitee is entitled under any provision
of this Agreement to indemnification by the Company for some or a portion of the
expenses, judgments, fines or penalties actually or reasonably incurred by him
in the investigation, defense, appeal or settlement of any civil or criminal
action, suit or proceeding, but not, however, for the total amount thereof, the
Company shall nevertheless indemnify Indemnitee for the portion of such
expenses, judgments, fines or penalties to which Indemnitee is entitled.

     5. MUTUAL ACKNOWLEDGEMENT. Both the Company and Indemnitee acknowledge that
in certain instances, Federal law or applicable public policy may prohibit the
Company from indemnifying its directors and officers under this Agreement or
otherwise. Indemnitee understands and acknowledges that the Company has
undertaken or may be required in the future to undertake with the Securities and
Exchange Commission to submit the question of indemnification to a court in
certain circumstances for a determination of the Company's right under public
policy to indemnify Indemnitee.

     6. OFFICER AND DIRECTOR LIABILITY INSURANCE. The Company shall, from time
to time, make the good faith determination whether or not it is practicable for
the Company to obtain and maintain a policy or policies of insurance with
reputable insurance companies providing the officers and directors of the
Company with coverage for losses from wrongful acts, or to ensure the Company's
performance of its indemnification obligations under this Agreement. Among other
considerations, the Company will weigh the costs of obtaining such insurance
coverage against the protection afforded by such coverage. In all policies of
director and officer liability insurance, Indemnitee shall be named as an
insured in such a manner as to provide Indemnitee the same rights and benefits
as are accorded to the most favorably insured of the Company's directors, if
Indemnitee is a director; or of the Company's officers, if Indemnitee is not a
director of the Company but is an officer. Notwithstanding the foregoing, the
Company shall have no obligation to obtain or maintain such insurance if the
Company determines in good faith that such insurance is not reasonably
available, if the premium costs for such insurance are disproportionate to the
amount of coverage provided, if the coverage provided by such insurance is
limited by exclusions so as to provide an insufficient benefit, or if Indemnitee
is covered by similar insurance maintained by a subsidiary or parent of the
Company. In the event that the Company determines that it shall eliminate or
reduce the level of insurance coverage described herein applicable at any time
to Indemnitee, the Company shall

                                      -5-
<PAGE>

provide Indemnitee with thirty (30) days prior written notice prior to
effectuating such elimination or reduction.

     7. SEVERABILITY. Nothing in this Agreement is intended to require or shall
be construed as requiring the Company to do or fail to do any act in violation
of applicable law. The Company's inability, pursuant to court order, to perform
its obligations under this Agreement shall not constitute a breach of this
Agreement. The provisions of this Agreement shall be severable as provided in
this Section 7. If this Agreement or any portion hereof shall be invalidated on
any ground by any court of competent jurisdiction, then the Company shall
nevertheless indemnify Indemnitee to the full extent permitted by any applicable
portion of this Agreement that shall not have been invalidated, and the balance
of this Agreement not so invalidated shall be enforceable in accordance with its
terms.

     8. EXCEPTIONS. Any other provision herein to the contrary notwithstanding,
the Company shall not be obligated pursuant to the terms of this Agreement:

          (a) CLAIMS INITIATED BY INDEMNITEE. To indemnify or advance expenses
to Indemnitee with respect to proceedings or claims initiated or brought
voluntarily by Indemnitee and not by way of defense, except with respect to
proceedings brought to establish or enforce a right to indemnification under
this Agreement or any other statute or law or otherwise as required under
Section 145 of the Delaware General Corporation Law, but such indemnification or
advancement of expenses may be provided by the Company in specific cases if the
Board of Directors has approved the initiation or bringing of such suit; or

          (b) LACK OF GOOD FAITH. To indemnify Indemnitee for any expenses
incurred by the Indemnitee with respect to any proceeding instituted by
Indemnitee to enforce or interpret this Agreement, if a court of competent
jurisdiction determines that each of the material assertions made by the
Indemnitee in such proceeding was not made in good faith or was frivolous; or

          (c) INSURED CLAIMS. To indemnify Indemnitee for expenses or
liabilities of any type whatsoever (including, but not limited to, judgments,
fines, ERISA excise taxes or penalties, and amounts paid in settlement) which
have been paid directly to Indemnitee by an insurance carrier under a policy of
officers' and directors' liability insurance maintained by the Company.

          (d) CLAIMS UNDER SECTION 16(B). To indemnify Indemnitee for expenses
and the payment of profits arising from the purchase and sale by Indemnitee of
securities in violation of Section 16(b) of the Securities Exchange Act of 1934,
as amended, or any similar successor statute.

     9. CONSTRUCTION OF CERTAIN PHRASES.

          (a) For purposes of this Agreement, references to the "Company" shall
include, in addition to the resulting corporation, any constituent corporation
(including any constituent of a constituent) absorbed in a consolidation or
merger which, if its separate existence had continued, would have had power and
authority to indemnify its directors, officers, and employees or agents, so that
if Indemnitee is or was a director, officer, employee or agent of such
constituent corporation, or is or was serving at the request of such constituent
corporation as a director, officer, employee or

                                      -6-
<PAGE>

agent of another corporation, partnership, joint venture, trust or other
enterprise, Indemnitee shall stand in the same position under the provisions of
this Agreement with respect to the resulting or surviving corporation as
Indemnitee would have with respect to such constituent corporation if its
separate existence had continued.

          (b) For purposes of this Agreement, references to "other enterprises"
shall include employee benefit plans; references to "fines" shall include any
excise taxes assessed on Indemnitee with respect to an employee benefit plan;
and references to "serving at the request of the Company" shall include any
service as a director, officer, employee or agent of the Company which imposes
duties on, or involves services by, such director, officer, employee or agent
with respect to an employee benefit plan, its participants, or beneficiaries;
and if Indemnitee acted in good faith and in a manner Indemnitee reasonably
believed to be in the interest of the participants and beneficiaries of an
employee benefit plan, Indemnitee shall be deemed to have acted in a manner "not
opposed to the best interests of the Company" as referred to in this Agreement.

     10. COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall constitute an original.

     11. SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon the
Company and its successors and assigns, including any direct or indirect
successor by purchase, merger, consolidation or otherwise to all, substantially
all or a substantial part of the business or assets of the Company. This
Agreement shall inure to the benefit of Indemnitee and Indemnitee's heirs, legal
representatives, executives and administrators. The Company shall require and
cause any successor (whether direct or indirect, and whether by purchase,
merger, consolidation or otherwise) to all, substantially all or a substantial
part of the business or assets of the Company, to assume and agree in writing to
perform this Agreement in the same manner and to the same extent that the
Company would be required to perform if no such succession had taken place.

     12. ATTORNEYS' FEES. In the event that any action is instituted by
Indemnitee under this Agreement to enforce or interpret any of the terms hereof,
Indemnitee shall be entitled to be paid all court costs and expenses, including
reasonable attorneys' fees, incurred by Indemnitee with respect to such action,
unless as a part of such action, the court of competent jurisdiction determines
that each of the material assertions made by Indemnitee as a basis for such
action were not made in good faith or were frivolous. In the event of an action
instituted by or in the name of the Company under this Agreement or to enforce
or interpret any of the terms of this Agreement, Indemnitee shall be entitled to
be paid all court costs and expenses, including attorneys' fees, incurred by
Indemnitee in defense of such action (including with respect to Indemnitee's
counterclaims and cross-claims made in such action), unless as a part of such
action the court determines that each of Indemnitee's material defenses to such
action were made in bad faith or were frivolous.

     13. EFFECTIVENESS OF AGREEMENT. This Agreement shall be effective as of the
date set forth on the first page and may apply to acts or omissions of
Indemnitee which occurred prior to such date if Indemnitee was an officer,
director, employee or other agent of the Company, or was serving at the request
of the Company as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, as the time such act or
omission occurred.

                                      -7-
<PAGE>

     14. NOTICE. All notices, requests, demands and other communications under
this Agreement shall be in writing and shall be deemed duly given (i) if
delivered by hand and receipted for by the party addressee, on the date of such
receipt, or (ii) if mailed by domestic certified or registered mail with postage
prepaid, on the third business day after the date postmarked. Addresses for
notice to either party are as shown on the signature page of this Agreement, or
as subsequently modified by written notice.

     15. CONSENT TO JURISDICTION. The Company and Indemnitee each hereby
irrevocably consent to the jurisdiction of the courts of the State of Delaware
for all purposes in connection with any action or proceeding which arises out of
or relates to this Agreement and agree that any action instituted under this
Agreement shall be brought only in the state courts of the State of Delaware.

     16. WAIVER OF JURY. EACH OF THE PARTIES HERETO HEREBY AGREES TO WAIVE ITS
RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR
ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. THE SCOPE
OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT
MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS
AGREEMENT, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL
OTHER COMMON LAW AND STATUTORY CLAIMS. EACH PARTY HERETO FURTHER REPRESENTS AND
WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT
KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION
WITH LEGAL COUNSEL.

     17. CHOICE OF LAW. This Agreement shall be governed by and its provisions
construed in accordance with the laws of the State of Delaware, as applied to
contracts between Delaware residents entered into and to be performed entirely
within Delaware without regard to the conflict of law principles thereof.

     18. PERIOD OF LIMITATIONS. No legal action shall be brought and no cause of
action shall be asserted by or in the right of the Company against Indemnitee,
Indemnitee's estate, spouse, heirs, executors or personal or legal
representatives after the expiration of two years from the date of accrual of
such cause of action, and any claim or cause of action of the Company shall be
extinguished and deemed released unless asserted by the timely filing of a legal
action within such two-year period; PROVIDED, HOWEVER, that if any shorter
period of limitations is otherwise applicable to any such cause of action, such
shorter period shall govern.

     19. SUBROGATION. In the event of payment under this Agreement, the Company
shall be subrogated to the extent of such payment to all of the rights of
recovery of Indemnitee, who shall execute all documents required and shall do
all acts that may be necessary to secure such rights and to enable the Company
effectively to bring suit to enforce such rights.

     20. AMENDMENT AND TERMINATION. No amendment, modification, termination or
cancellation of this Agreement shall be effective unless it is in writing signed
by both the parties hereto. No waiver of any of the provisions of this Agreement
shall be deemed or shall constitute a waiver of any other provisions hereof
(whether or not similar) nor shall such waiver constitute a continuing waiver.

                                      -8-
<PAGE>

The failure of either party to enforce any rights under this Agreement shall not
be construed as a waiver of any rights of such party.

     21. INTEGRATION AND ENTIRE AGREEMENT. This Agreement sets forth the entire
understanding between the parties hereto and supersedes and merges all previous
written and oral negotiations, commitments, understandings and agreements
relating to the subject matter hereof between the parties hereto

                                      -9-
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the date first above written.

                                 CYTOKINETICS, INCORPORATED

                                 ---------------------------------------
                                 SIGNATURE OF AUTHORIZED SIGNATORY

                                 ---------------------------------------
                                 PRINT NAME AND TITLE

                                 Address:
                                         ---------------------------------------

                                         ---------------------------------------

AGREED TO AND ACCEPTED:

INDEMNITEE:

------------------------------
SIGNATURE

------------------------------
PRINT NAME AND TITLE

Address:
         ------------------------------

         ------------------------------

         ------------------------------<PAGE>
                                                                   Exhibit 10.45

                           CYTOKINETICS, INCORPORATED

                         COMMON STOCK PURCHASE AGREEMENT

      THIS COMMON STOCK PURCHASE AGREEMENT (the "AGREEMENT") is made as of March
___, 2004 by and among Cytokinetics, Incorporated, a Delaware corporation (the
"COMPANY"), and Glaxo Group Limited (the "INVESTOR").

                                    RECITALS

      A. Whereas, the Company has authorized the sale and issuance of shares of
its Common Stock (the "Stock") at a per share purchase price (the "PER SHARE
PRICE") equal to the per share purchase price to the public in the Company's
initial public offering of shares of its Common Stock pursuant to a registration
statement on Form S-1, as amended (the "REGISTRATION STATEMENT") filed with the
Securities and Exchange Commission (the "IPO").

      B. Whereas, the Company has determined that it is in the best interests of
the Company and its stockholders to allow the Investor to make the investment in
the Company provided for, and on the terms and conditions set forth, in this
Agreement.

      C. Whereas, the Investor desires to make such investment on such terms and
conditions.

      NOW, THEREFORE, in consideration of the premises and the mutual covenants
and conditions herein contained, the Company and the Investor hereby agree as
follows:

                                    SECTION 1

                           PURCHASE AND SALE OF SHARES

      1.1   AUTHORIZATION OF THE STOCK. On or prior to the Closing (as defined
in SECTION 1.4 below), the Company shall have authorized the sale and issuance
of the Stock to the Investor.

      1.2   SALE OF THE STOCK. Subject to the terms and conditions hereof, the
Company will issue and sell to the Investor, and the Investor will purchase from
the Company, at the Closing, that number of whole shares of Stock equal to the
quotient obtained by dividing the dollar amount set forth opposite the
Investor's name on the Schedule of Purchasers attached hereto as SCHEDULE A by
the Per Share Price.

      1.3   PRE-CLOSING. A pre-closing to the purchase and sale of the Stock
contemplated by this Agreement shall be held at 10:00 a.m. at the offices of
Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050
on the date one day prior to the Closing (or such other time and date upon which
the parties may agree). The Company shall provide to the Investor with notice of
the date and time of such pre-closing not later than twenty-four (24) hours
prior to the pre-closing. Notwithstanding the provisions of Section 7.4 below,
such notice may be oral. At the pre-closing the Investor shall transfer to the
Wilson Sonsini Goodrich & Rosati trust account the aggregate purchase price for
the Stock to be purchased by the Investor by check payable to the order of the
<PAGE>
Company or by wire transfer pursuant to wire transfer instructions delivered to
the Investor by the Company, which purchase price shall be held in escrow by
Wilson Sonsini Goodrich & Rosati until the Closing.

      1.4   CLOSING. The purchase and sale of the Stock shall take place at a
closing (the "CLOSING") to be held at the offices of Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050, immediately prior to the
closing of the Company's IPO (the "CLOSING DATE"). At the Closing, the Company
will deliver or cause to be delivered to the Investor a certificate or
certificates representing the Stock that the Investor is purchasing and,
concurrently, Wilson Sonsini Goodrich & Rosati shall release from escrow and
deliver to the Company by wire transfer the purchase price for such Stock.

                                    SECTION 2

                  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

      The Company hereby represents and warrants as follows:

      2.1   ORGANIZATION AND GOOD STANDING AND QUALIFICATIONS. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has all requisite corporate power and authority to
carry on its business as currently conducted and as proposed to be conducted.
The Company is duly qualified to transact business and is in good standing in
each jurisdiction in which the failure to so qualify would have a material
adverse effect on its business or properties. True and accurate copies of the
Company's Amended and Restated Certificate of Incorporation (the "RESTATED
CERTIFICATE") and Bylaws, as amended, and each as in effect at the Closing have
been provided to the Investor.

      2.2   AUTHORIZATION. All corporate action on the part of the Company, its
officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement, the performance of all obligations of the
Company hereunder, and the authorization, issuance, sale and delivery of the
Stock has been taken or will be taken prior to the Closing, and this Agreement
constitutes a valid and legally binding obligation of the Company, enforceable
in accordance with its terms, subject only to: (i) judicial principles limiting
the availability of specific performance, injunctive relief, and other equitable
remedies; and (ii) bankruptcy, insolvency, reorganization, moratorium or other
similar laws now or hereafter in effect generally relating to or affecting
creditors' rights.

      2.3   VALID ISSUANCE OF STOCK. The Stock when issued, sold and delivered
in accordance with the terms of this Agreement for the consideration expressed
herein, will be duly and validly issued, fully paid, and nonassessable, and will
be free of restrictions on transfer other than restrictions on transfer under
this Agreement and under applicable state and federal securities laws.

      2.4   GOVERNMENTAL CONSENTS. No consent, approval, order or authorization
of, or registration, qualification, designation, declaration or filing with, any
federal, state or local governmental authority on the part of the Company is
required in connection with the offer, sale or issuance of the Stock, except for
the following: (i) the filing of the Restated Certificate in the office

                                                                             -2-
<PAGE>
of the Secretary of State of the State of Delaware, which shall be filed by the
Company on or prior to the Closing; (ii) the filing of such notices as may be
required under the Securities Act of 1933, as amended (the "SECURITIES ACT");
and (iii) the compliance with applicable state securities laws, which compliance
will have occurred within the appropriate time periods therefor. Based in part
on the representations of the Investor set forth in Section 3 below, the offer,
sale and issuance of the Stock in conformity with the terms of this Agreement
are exempt from the registration requirements of Section 5 of the Securities Act
and from the registration or qualification requirements of applicable state
securities laws.

      2.5   COMPLIANCE WITH OTHER INSTRUMENTS. The Company is not in violation
or default of any provision of its Restated Certificate or Bylaws, as amended,
and each in effect on and as of the Closing. The Company is not in violation or
default of any material provision of any instrument, mortgage, deed of trust,
loan, contract, commitment, judgment, decree, order or obligation to which it is
a party or by which it or any of its properties or assets are bound which would
materially adversely affect the financial condition, business, property, assets
or liabilities of the Company or of any provision of any federal, state or, to
its knowledge, local statute, rule or governmental regulation which would
materially adversely affect the financial condition, business, property, assets
or liabilities of the Company. The execution, delivery and performance of and
compliance with this Agreement, and the issuance and sale of the Stock will not
result in any such violation, be in conflict with or constitute, with or without
the passage of time or giving of notice, a default under any such provision,
require any consent or waiver under any such provision (other than any consents
or waivers that have been obtained), or result in the creation of any mortgage,
pledge, lien, encumbrance or charge upon any of the properties or assets of the
Company pursuant to any such provision.

                                    SECTION 3

                 REPRESENTATIONS AND WARRANTIES OF THE INVESTOR

      The Investor hereby represents and warrants that:

      3.1   EXPERIENCE. The Investor is experienced in evaluating companies such
as the Company, is able to fend for itself in transactions such as the one
contemplated by this Agreement, has such knowledge and experience in financial
and business matters that the Investor is capable of evaluating the merits and
risks of the Investor's prospective investment in the Company, and has the
ability to bear the economic risks of the investment.

      3.2   INVESTMENT. The Investor is acquiring the Stock for investment for
the Investor's own account and not with the view to, or for resale in connection
with, any distribution thereof. The Investor understands that the Stock has not
been registered under the Securities Act by reason of a specific exemption from
the registration provisions of the Securities Act which depends upon, among
other things, the bona fide nature of the investment intent as expressed herein.
The Investor acknowledges and agrees that the Stock purchased by the Investor,
until disposition of such Stock in accordance with the provisions of this
Agreement, shall remain at all times within the Investor's control. The Investor
further represents that it does not have any contract, undertaking, agreement or
arrangement with any person to sell, transfer or grant participation to any
third person with respect to

                                                                             -3-
<PAGE>
any of the Stock. The Investor understands and acknowledges that the offering of
the Stock pursuant to this Agreement will not be registered under the Securities
Act on the ground that the sale provided for in this Agreement and the issuance
of securities hereunder is exempt from the registration requirements of the
Securities Act.

      3.3   RULE 144. The Investor acknowledges that the Stock must be held
indefinitely unless subsequently registered under the Securities Act or an
exemption from such registration is available. The Investor is aware of the
provisions of Rule 144 promulgated under the Securities Act which permit limited
resale of shares purchased in a private placement subject to the satisfaction of
certain conditions. The Investor covenants that, in the absence of an effective
registration statement covering the stock in question, the Investor will sell,
transfer, or otherwise dispose of the Stock only in a manner consistent with the
Investor's representations and covenants set forth in this Section 3. In
connection therewith, the Investor acknowledges that the Company will make a
notation on its stock books regarding the restrictions on transfers set forth in
this Section 3 and will transfer securities on the books of the Company only to
the extent not inconsistent therewith.

      3.4   ACCESS TO INFORMATION. The Investor has received and reviewed
information about the Company and has had an opportunity to discuss the
Company's business, management and financial affairs with its management and to
review the Company's facilities. The Investor has carefully reviewed the
information prepared by the Company in connection with this offering and has
been furnished with all other materials that it considers relevant to its
investment in the Stock. The Investor has had a full opportunity to ask
questions of and receive answers from the Company, or any person or persons
acting on behalf of the Company, concerning the terms and conditions of an
investment in the Stock. The Investor understands that such discussions were
intended to describe the aspects of the Company's business and prospects which
the Company believes to be material, but were not necessarily a thorough or
exhaustive description. No statement or printed material contrary to the
information contained in the information has been made or given to the Investor
by or on behalf of the Company. The Investor is not relying upon, and has not
relied upon, any statement, representation or warranty made by any person,
including without limitation, any of the Company's underwriters, except for the
statements, representations and warranties contained in this Agreement.

      3.5   AUTHORIZATION. This Agreement when executed and delivered by the
            Investor will constitute a valid and legally binding obligation of
the Investor, enforceable in accordance with its terms, subject to: (i) judicial
principles respecting election of remedies or limiting the availability of
specific performance, injunctive relief, and other equitable remedies; and (ii)
bankruptcy, insolvency, reorganization, moratorium or other similar laws now or
hereafter in effect generally relating to or affecting creditors' rights.

      3.6   INVESTOR STATUS. The Investor acknowledges that it is either (i) an
institutional "accredited investor" as defined in Rule 501(a) of Regulation D of
the Securities Act (an "Institutional Accredited Investor") or (ii) a "qualified
institutional buyer" as defined in Rule 144A of the Securities Act, as indicated
on SCHEDULE A hereto, and the Investor shall submit to the Company such further
assurances of such status as may be reasonably requested by the Company.

                                                                             -4-
<PAGE>
      3.7   FOREIGN INVESTOR. The Investor hereby represents that it has
satisfied itself as to the full observance of the laws of its jurisdiction in
connection with any invitation to subscribe for the Stock or any use of this
Agreement, including (i) the legal requirements within its jurisdiction for the
purchase of the Stock, (ii) any foreign exchange restrictions applicable to such
purchase, (iii) any governmental or other consents that may need to be obtained,
and (iv) the income tax and other tax consequences, if any, that may be relevant
to the purchase, holding, redemption, sale, or transfer of the Stock. The
Investor's subscription and payment for and continued beneficial ownership of
the Stock, will not violate any applicable securities or other laws of the
Investor's jurisdiction.

      3.8   NO INDUCEMENT. The Investor was not induced by the filing of the
Registration Statement in connection with the Company's IPO to participate in
the offer and sale of the Stock, and the Investor's decision to so participate
was not influenced by the information contained in the Registration Statement.

                                    SECTION 4
                 CONDITIONS TO INVESTOR'S OBLIGATIONS AT CLOSING

      The obligations of the Investor under this Agreement are subject to the
fulfillment on or before the Closing of each of the following conditions, any of
which may be waived in writing by the Investor:

      4.1   NO INJUNCTION, ETC. No preliminary or permanent injunction or other
binding order, decree or ruling issued by a court or governmental agency shall
be in effect which shall have the effect of preventing the consummation of the
transactions contemplated by this Agreement.

      4.2   REPRESENTATIONS AND WARRANTIES. The representations and warranties
of the Company contained in SECTION 2 shall be true and correct on and as of the
Closing with the same effect as though such representations and warranties had
been made on and as of the date of the Closing.

      4.3   PERFORMANCE. The Company shall have performed and complied with all
covenants, agreements, obligations and conditions contained in this Agreement
that are required to be performed or complied with by it on or before each
Closing.

      4.4   COMPLIANCE CERTIFICATE. A duly authorized officer of the Company
shall deliver to the Investor at the Closing a certificate stating that the
conditions specified in Sections 4.2 and 4.3 have been fulfilled.

      4.5   SECURITIES LAWS. The offer and sale of the Stock to the Investor
pursuant to this Agreement shall be exempt from the registration requirements of
the Securities Act and the registration and/or qualification requirements of all
applicable state securities laws.

      4.6   CORPORATE PROCEEDINGS. All corporate and other proceedings required
to carry out the transactions contemplated by this Agreement, and all
instruments and other documents relating to such transactions, shall be
reasonably satisfactory in form and substance to the Investor and its

                                                                             -5-
<PAGE>
counsel, and the Investor shall have been furnished with such instruments and
documents as such counsel shall have reasonably requested.

      4.7   INITIAL PUBLIC OFFERING. The Registration Statement prepared in
connection with the Company's IPO shall have been filed with, and declared
effective by, the Securities and Exchange Commission.

      4.8   AUTHORIZATIONS. All authorizations, approvals or permits, if any, of
any governmental authority or regulatory body that are required in connection
with the lawful issuance and sale of the Stock pursuant to this Agreement shall
have been duly obtained and shall be effective on and as of the Closing.

                                    SECTION 5

               CONDITIONS TO THE COMPANY'S OBLIGATIONS AT CLOSING

      The obligations of the Company to the Investor under this Agreement are
subject to the fulfillment on or before each Closing of each of the following
conditions by the Investor:

      5.1   REPRESENTATIONS AND WARRANTIES. The representations and warranties
of the Investor contained in Section 3 shall be true and correct on and as of
the Closing with the same effect as though such representations and warranties
had been made on and as of the Closing.

      5.2   SECURITIES LAW COMPLIANCE. The offer and sale of the Stock to the
Investor pursuant to this Agreement shall be exempt from the registration
requirements of the Securities Act and the registration and/or qualification
requirements of all applicable state securities laws.

      5.3 AUTHORIZATION. All authorizations, approvals or permits, if any, of
any governmental authority or regulatory body that are required in connection
with the lawful issuance and sale of the Stock pursuant to this Agreement shall
have been duly obtained and shall be effective on and as of the Closing.

      5.4 CORPORATE PROCEEDINGS. All corporate and other proceedings
contemplated at the Closing hereby, and all documents and instruments incident
to these transactions, shall be reasonably satisfactory in substance to the
Company and its counsel.

      5.5 LOCK-UP AGREEMENT. The Investor shall have delivered to Goldman, Sachs
& Co. an executed Lock-Up Agreement in the form attached hereto as EXHIBIT A.

      5.6 PAYMENT OF PURCHASE PRICE. The Investor shall have delivered to the
Company the purchase price for the Stock as set forth in Section 1.4 hereof.

                                    SECTION 6

                               INVESTOR COVENANTS

                                                                             -6-
<PAGE>
      6.1   RESTRICTIONS ON RESALE OF STOCK.

            (a) The Investor agrees that during the Research Term (as such term
is defined in the Collaboration and License Agreement between the parties dated
June 20, 2001, but not to include any extensions of the initial Research Term
(the "Restriction Term")), the Investor shall not offer, sell, contract to sell,
pledge, grant any option to purchase, make any short sale or otherwise dispose
of in any manner, either directly or indirectly ("Sale" or "Sell"), the Stock
purchased pursuant to this Agreement (the "Covenant Shares"), provided that,
nothing in the foregoing sentence shall prevent the Investor from participating
in, and selling the Covenant Shares through, registrations of the Company's
Common Stock ("Common Stock") pursuant to the provisions of Section 1.3 of the
Company's Amended and Restated Investors' Rights Agreement dated March 21, 2003,
as amended.

            (b) After the expiration of such Restriction Term the Investor and
the Company agree and acknowledge that it is in their mutual interest that
disposition of the Covenant Shares be accomplished in a manner that does not
disrupt or undermine the trading market for Common Stock (including any undue
adverse reaction to the fact of sale of Covenant Shares by the investor as a
research collaborator of the Company), and the parties will work together to
explore methods of disposition in order to achieve such goal.

            (c) Notwithstanding anything to the contrary in this Section 6.1,
after the period that is 180 days after IPO the Investor may sell Covenant
Shares, if (i) the publicly traded fair market value per share of publicly
traded shares of Common Stock, at the time of the sale by the Investor of
Covenant Shares, is greater than two and a half times the per share price (as
adjusted for combination, stock splits, stock dividends, subdivisions or
split-ups) that shares of Common Stock were initially offered to the public in
the IPO (the "IPO Price") and (ii) no sales by the Investor of shares of
Covenant Shares are at a price per share less than two and a half times (as
adjusted for combination, stock splits, stock dividends, subdivisions or
split-ups) the IPO Price. If the Investor intends to sell any Covenant Shares
held by it pursuant to the provisions of this Section 6.1(c), the Investor and
the Company agree and acknowledge that it is in their mutual interest that
disposition of the Covenant Shares be accomplished in a manner that does not
disrupt or undermine the trading market for the Company's Common Stock
(including any undue adverse reaction to the fact of sale of Covenant Shares by
the investor as a research collaborator of the Company), and the parties will
work together to explore methods of disposition in order to achieve such goal.
Investor agrees to execute a lockup agreement covering sales of Covenant Shares
during the 180-day period following the IPO as requested by the underwriters in
the IPO.

                                                                             -7-
<PAGE>
                                    SECTION 7

                                  MISCELLANEOUS

      7.1   GOVERNING LAW. This Agreement shall be governed in all respects by
the laws of the State of California as applied to agreements entered into and
performed entirely in the State of California by residents thereof.

      7.2   SURVIVAL. The representations, warranties, covenants and agreements
made herein shall survive any investigation made by the Investor and the closing
of the transactions contemplated hereby.

      7.3   SUCCESSORS, ASSIGNS. Except as otherwise provided herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the
successors, assigns, heirs, executors and administrators of the parties hereto.

      7.4   NOTICES. All notices and other communications required or permitted
hereunder shall be in writing and shall be sent by facsimile or mailed by
registered or certified mail, postage prepaid, return receipt requested, or
otherwise delivered by hand or by messenger, addressed (a) if to an Investor, at
such address as the Investor shall have furnished to the Company in writing, or
(b) if to the Company, at the following address:

                  Cytokinetics, Incorporated
                  280 E Grand Ave, Suite #2
                  South San Francisco, CA 94080

or at such other address as the Company shall have furnished to the Investor. If
notice is provided by facsimile, it shall be deemed to be given one (1) business
day after transmission (with receipt of appropriate confirmation). If notice is
provided by U.S. mail, notice shall be deemed to be given four (4) days after
proper deposit in a U.S. mailbox, postage prepaid, and addressed to the parties
at the addresses provided to the Company or such other address as a party may
request by notifying the other in writing. If notice is provided by a messenger
service that guarantees "next business day" delivery, it shall be deemed
effective one (1) business day after deposit with such messenger service.

      7.5   EXPENSES. The Company and the Investor shall bear their own expenses
and legal fees incurred on their behalf with respect to this Agreement and the
transactions contemplated hereby.

      7.6   FINDER'S FEES. The Company and the Investor shall each indemnify and
hold the other harmless from any liability for any commission or compensation in
the nature of a finder's fee, placement fee or underwriter's discount (including
the costs, expenses and legal fees of defending against such liability) for
which the Company or the Investor, or any of their respective partners,
employees, or representatives, as the case may be, is responsible.

      7.7   COUNTERPARTS. This Agreement may be executed in counterparts, each
of which shall be enforceable against the party actually executing the
counterpart, and all of which together shall constitute one instrument.

                                                                             -8-
<PAGE>
      7.8   SEVERABILITY. In the event that any provision of this Agreement
becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable or void, this Agreement shall continue in full force and effect
without said provision; provided that no such severability shall be effective if
it materially changes the economic benefit of this Agreement to any party.

                                                                             -9-
<PAGE>
      IN WITNESS WHEREOF, the parties have executed this Stock Purchase
Agreement as of the date first set forth above.

CYTOKINETICS, INCORPORATED                GLAXO GROUP LIMITED

By:                                       By:
   -----------------------------------    --------------------------------------

Name:                                     Name:
     ---------------------------------    --------------------------------------

Title:                                    Title:
      --------------------------------    --------------------------------------

                  SIGNATURE PAGE TO CYTOKINETICS, INCORPORATED
                         COMMON STOCK PURCHASE AGREEMENT
<PAGE>
                                   SCHEDULE A

                             SCHEDULE OF PURCHASERS

<TABLE>
<CAPTION>
Name                      Investment Amount    Type of Investor
----                      -----------------    ---------------------------------
<S>                       <C>                  <C>

Glaxo Group Limited       $7,000,000.00        Institutional Accredited Investor
</TABLE>
<PAGE>
                                    EXHIBIT A

                                LOCK-UP AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]